Premium
Quantification of epidermal growth factor receptor ( EGFR ) in canine mammary tumours by ELISA assay: clinical and prognostic implications
Author(s) -
Queiroga F. L.,
PerezAlenza M. D.,
GonzálezGil A.,
Silván G.,
Peña L.,
Illera J. C.
Publication year - 2017
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12174
Subject(s) - epidermal growth factor receptor , epidermal growth factor , medicine , mammary gland , breast cancer , pathology , metastasis , cancer , human epidermal growth factor receptor 2 , immune system , cancer research , receptor , oncology , biology , immunology
The involvement of epidermal growth factor receptor ( EGFR ) is well established in human breast cancer, however, in canine mammary tumours ( CMT ), including inflammatory mammary carcinomas ( IMC ), still needs to be clarified. Enzyme immune assay techniques were used for EGFR determinations in tumour tissue from 45 bitches with CMT and in normal mammary glands from eight control dogs. Higher tissue EGFR levels were found in CMT compared with controls ( P < 0.05). In malignant CMT , tissue EGFR elevated concentrations were statistically significantly associated with tumour relapse and/or distant metastasis during follow‐up and with reduced disease‐free and overall survival times. The IMC cases had the highest tissue EGFR levels compared with other malignant non‐ IMC tumours ( P < 0.001). The results support the hypothesis that EGFR levels influence prognosis in malignant CMT , suggesting that EGFR may represent a therapeutic target in cases of high histological aggressiveness and especially in cases of metastatic phenotype and poor prognosis.